Weekly Investment Analysts’ Ratings Changes for Mereo BioPharma Group (MREO)

Mereo BioPharma Group (NASDAQ: MREO) recently received a number of ratings updates from brokerages and research firms:

• 1/3/2026 – Mereo BioPharma Group was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/30/2025 – Mereo BioPharma Group was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating.
• 12/29/2025 – Mereo BioPharma Group was given a new $1.00 price target on by analysts at Robert W. Baird.
• 12/29/2025 – Mereo BioPharma Group had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 12/29/2025 – Mereo BioPharma Group was downgraded by analysts at Lifesci Capital from an “outperform” rating to a “hold” rating.
• 12/29/2025 – Mereo BioPharma Group had its price target lowered by analysts at BTIG Research from $6.00 to $1.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Mereo BioPharma Group had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
• 12/18/2025 – Mereo BioPharma Group had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.
• 11/12/2025 – Mereo BioPharma Group was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.